Ming-Hui
Zou MD PhD
Chief,
Section of Molecular Medicine
Vice
Chair for Research, Department of Medicine
Warren
Chair in Diabetes Research
Professor
of Medicine, Biochemistry and Molecular Biology
University
of Oklahoma Health Science Center
Phone:
405-271-3974, Fax: 405-271-3973
email:
ming-hui-zou@ouhsc.edu
Website:
http://www.oumedicine.com/body.cfm?id=6122
Mailing Address:
BSEB
306A
941 Stanton L. Young Blvd.
Oklahoma City, OK 73104
USA
Ming-Hui Zou, Ph.D. graduated from Hubei Medical College at Xianning with a Bachelor’s degree in Medicine in 1985. He obtained
his Ph.D. (Pharmacology) in France in 1994 and his Doctor of Science (Biological Chemistry) in 1999 in Germany. Dr. Zou became Assistant Professor at Boston
University School of Medicine in 2000 and Associate Professor at University of Tennessee in 2003. Since May 2005, Dr. Zou has been appointed as Professor of
Medicine, and Professor of Biochemistry and Molecular Biology (tenure) at University of Oklahoma Health Science Center. He currently serves as the Chief of
the section of Molecular Medicine and vice chairman for research, Department of
Medicine. He also holds the Travis Endowed Chair in Endocrinology (since 2005) and the Warren Endowed Chair Professorship in Diabetes Research (since 2010) at the University of Oklahoma Health Science Center.
Dr. Zou has been productively working in
the area of cardiovascular biology and diseases for 20 years. Dr. Zou’s ongoing
research programs focus on the means to sense oxidative stress, reduce it, or
ameliorate the body’s adverse response to it. . Dr. Zou was instrumental in
examining the role of nitric oxide and oxidative stress in the regulation of
blood flow and vascular function. He performed elegant, state-of-the-art
studies to show that the selective modification of two key proteins,
prostacyclin synthase and endothelial nitric oxide synthase, is critical in the
deregulation of vessel function from nitric oxide and superoxide. Dr. Zou’s
group was also the first to demonstrate that the AMP-activated kinase (AMPK), a key enzyme in the regulation of energy metabolism, obesity, diabetes, and
cardiovascular diseases, functions as a sensor and regulator of oxidative
stress. Dr. Zou’s contributions in this area are significant and his work
represents outstanding breakthrough research, which has been recognized by many
other investigators in the fields. An independent investigator of the National
Institutes of Health, the Juvenile Diabetes Research Foundation International (JDRF), and the American Diabetes Association, and a National Scientist Development (SDG) and National Established Investigator (EIA) awardee of the American Heart Association, Dr.
Zou has used these (and many other awards) to make scientific observations in
fields with great potential for immediate clinical relevance. Since 2005, Dr.
Zou has served on several national study panels such as the National Institutes
of Health, American Heart Association, and American Diabetes Association and on
many international panels including the National Science Foundation of China,
the Research Grant Council and the University of Grant Committee of Hong Kong,
the Wellcome Trust of England, and German Science Foundation (DFG). He is also the Editor-in-chief for the journals “Diabetes, Metabolic Syndrome and
Obesity” “World Journal of Diabetes” and has served the editorial boards of
many prestigious journals including ATVB, Diabetes, etc. In past three years, he has published 45 peer
reviewed papers in highly impacted journals including Circulation、Circulation
Research, J. Clin. Invest.,Diabetes, Mol. Cell. Biol. Atherosclerosis, Vascular
Biology, and Thrombosis、J. Biol. Chem.,
Hypertension.In 2008 he was elected to the American Society for
Clinical Investigation, one of the United States’ oldest honor societies of
physician-scientists, membership in which reflects accomplishments by its
members at an early stage (<45 years old) in their careers.
邹明辉，医学博士；哲学博士
分子医学系主任
医学系副主任
糖尿病研究中心Warren Chair
医学生物化学与分子生物学教授
俄克拉荷马大学医学院
电话：1-405-271-3974 传真：1-405-271-3973
电邮：ming-hui-zou@ouhsc.edu
网址：http://www.oumedicine.com/body.cfm?id=6122
通讯地址：BSEB 306A, 941 Stanton L. Young Blvd., Oklahoma City, OK 73104, USA
邹明辉博士1985年毕业于湖北医学院咸宁分院，获医学学士学位。1994年于法国获药理学博士学位，1999年于德国获生物化学博士学位。2000年，受聘于波士顿大学助理教授，2003年受聘为田纳西大学副教授。自2005年起，邹博士被聘为俄克拉荷马大学医学院生物化学与分子生物学终身教授，现任俄克拉荷马大学医学院分子医学系主任，医学系副主任，兼任俄克拉荷马大学医学院Travis
Endowed Chair内分泌讲座教授 和Warren Endowed Chair 糖尿病讲座教授。
邹明辉博士研究心血管生物学及糖尿病已20多年.
目前他主要研究氧化应激在心血管疾病发生发展中的作用，就如何有效地检测机体的氧化应激反应、减低机体氧化应激反应以及增强机体的抗氧化应激能力作出了许多原创性成果。他专长于研究一氧化氮和氧化应激在血流学和血管功能学的作用，并对前列环素和内皮一氧化氮合酶的修饰作用进行了系统性和开拓性研究，发现它们是介导一氧化氮和超氧化物的血管功能的关键物质。他的研究团队亦首次发现AMP活化的蛋白激酶（AMPK）除了能感受细胞能量不足外，并主动参与细胞能量代谢调节，是肥胖症、糖尿病和心血管疾病的发生环节中的一个关键酶。
邹明辉博士的研究推动了相关领域的发展，他的工作完全得到了同行们的认可，并得到美国国立卫生研究院（NIH）、美国糖尿病协会（ADA）和美国心脏病协会（AHA）等基金的重点资助。他的研究成果也充分应用到临床工作中，对指导临床治疗有重要意义。自2005年起，邹明辉博士是美国国立卫生研究院、美国糖尿病协会、美国心脏病协会的基金评委及多项国际研究组织，如中国国家自然科学基金、香港大学研究基金、英国Wellcome Trust基金组织和德国科学基金的特邀评委。邹明辉博士还任《Diabetes, Metabolic Syndrome and Obesity》《World Journal of Diabetes》杂志主编及多项国际权威杂志的编委，如ATVB、Diabetes。在过去的3年中在国际著名杂志
Circulation、Circulation Research, J.
Clin. Invest.,Diabetes, Mol. Cell. Biol. Atherosclerosis, Vascular Biology, and
Thrombosis、J. Biol. Chem., Hypertension 等国际学术期刊发表学术论文45余篇。2008年，由于他在氧化应激和血管功能的调节方面做出了重要贡献，邹明辉博士被美国最悠久和最有声望的医生—科学家组织—美国临床研究协会（American
Society for Clinical Investigation）遴选为会员。
Selected 10 publications in last three years
1.
Xie, Z., Song, P., Zhang, M., Zou,
M.H. Up-regulation of Mitochondrial
Uncoupling Protein-2 by the AMP-activated Protein Kinase in Endothelial Cells
Attenuates Oxidative Stress in Diabetes. Diabetes. 57(12):3222-30, 2008. PMCID2584127
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584127/pdf/3222.pdf
2.
Zhang M., Dong, Y., Xu,
J., Xie, Z., Wu, Y., Song, P., Guzman, M., and Zou, M.H. Thromboxane
receptor via hydrogen peroxide activates the AMP-activated kinase in vascular
smooth muscle cells. Circulation Research 102:328-337, 2008 PMID: 18063812 PMC2869198
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2869198/pdf/nihms95999.pdf
3.
Xie Z, Dong Y, Scholz R,
Neumann D, and Zou,M.H. Phosphorylation of LKB1 at serine 428 by protein
kinase C-z is required for metformin-enhanced activation of
the AMP-activated protein kinase in endothelial cells. Circulation
117:952-962, 2008 PMID: 18250273
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2862466/pdf/nihms96004.pdf
4.
Xie Z, Dong Y, Zhang J,
Scholz R, Neumann D, Zou, M.H. Identification of the serine 307 of LKB1 as a novel phosphorylation
site essential for its nucleocytoplasmic transport and endothelial cell
angiogenesis. Mol Cell
Biol. 13:3582-3596; 2009. PMCID2698771
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2862466/pdf/nihms96004.pdf
5.
Xu,
J., and Zou, M.H. Molecular
Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction. Circulation.
120(13):1266-86, 2009 PMID: 19786641 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910587/pdf/nihms215845.pdf
6.
Wang,
S., Zhang, M., Xu, J., Song, P., and Zou, M.H. In Vivo Activation of AMP-activated Protein Kinase Attenuates
Diabetes-enhanced Degradation of GTP Cyclohydrolase I. Diabetes.
58(8):1893-901, 2009 PMID:
19528375
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2712774/pdf/zdb1893.pdf
7.
Dong, Y., Zhang,
M., Wang, S., Liang, B., Zhao, Z., Liu, C., Wu, M., Choi, H., Lyons, T., Zou,
M.H., Activation of AMP-activated protein kinase inhibits oxidized
LDL-triggered endoplasmic reticulum stress in vivo. Diabetes
59(6):1386-96, 2010 PMCID: PMC2874699
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874699/pdf/zdb1386.pdf
8.
Wang, S., Zhang, M.,
Xie, Z., Viollet, B., Zou, M.H. AMPKalpha2 deletion accelerates
atherosclerosis by increasing 26S proteasome-dependent degradation of I-kappa B
and NAD(P)H oxidase expression. Circulation
Research
106:1117-28, 2010. PMCID: PMC2888409
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920052/pdf/nihms190259.pdf
9.
Dong, Y., Zhang, M.,
Liang, B., Xie, Z., Choi, H., Zou, M.H., Reduction of AMP-activated
protein kinase alpha 2 increased endoplasmic reticulum stress and
atherosclerosis in vivo. Circulation 121(6):792-803, 2010. PMCID: PMC2825900
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825900/pdf/nihms172832.pdf
10. Xie Z, Lau K, Eby B, Lozano P, He C, Pennington B,
Dong Y, Rathi S, Tian R, Kem D, Zou, M.H. Improvement of cardiac
functions by chronic metformin treatment is associated with enhanced cardiac
autophagy in diabetic OVE26 mice. Diabetes. 60(6):1770-8, 2011. NIHMSID # 315880
http://diabetes.diabetesjournals.org/content/60/6/1770.full.pdf+html